ALK and non-small cell lung carcinoma: To address these fundamental challenges and concretely enhance access to research and inclusivity for patients with advanced ALK+ NSCLC, we launched and implemented the “Elucidating Novel Immune and Genomic Markers for ALK+ (ENIGMA+)” study.